Cosmetic Compliance
Intelligence & Solutions
Home / News / Details

[Updated] Japan Approves the Amendments to Good Manufacturing Practice for Quasi-drugs

Quasi-drug manufacturers shall prepare product standard code and procedure manuals in each factory. Tests and inspections of imported quasi-drugs can be replaced by the testing and inspection records of foreign manufacturers when certain conditions are met.

On Apr. 30, 2021, Japan Ministry of Health, Labour and Welfare (MHLW) officially approved the Ministerial Ordinance on the Good Manufacturing Practice for Quasi-Drugs and Pharmaceuticals. The amendments to the Good Manufacturing Practice for quasi-drugs will take effect on August 1st 2021.


On Nov. 27, 2020, Japan Ministry of Health, Labour and Welfare (MHLW) released the amendment to the Ministerial Ordinance on the Good Manufacturing Practice for Quasi-Drugs and Pharmaceuticals (hereinafter referred to as updated GMP Ministerial Ordinance) for public consultation. Advice and suggestions should be submitted before Dec. 26, 2020.

This updated GMP Ministerial Ordinance consists of 3 chapters and 53 articles. Compared with the previous edition, it refines the compliance requirements for the manufacturing and quality management of the manufacturing facility of pharmaceuticals and quasi-drugs, which includes

Please Log in or Sign up (FREE) to read the full content.
Tags : JapanGMP
We provide full-scale Chinese cosmetic market entry services (including cosmetic registering & filing, regulatory consultation, customized training, market research, branding strategy). Please contact us to discuss how we can help you by
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact